Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Fulcrum Therapeutics (FULC)
NASDAQ:FULC
Fulcrum Therapeutics (FULC) Stock Price & Analysis
452 Followers
FULC Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$3.14 - $13.70
Previous Close$8
Volume434.95K
Average Volume (3M)794.63K
Market Cap
$497.23M
Enterprise Value$294.05M
Total Cash (Recent Filing)$213.31M
Total Debt (Recent Filing)$10.14M
Price to Earnings (P/E)―
Beta1.75
Next Earnings
Aug 07, 2024EPS Estimate
-$0.41Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.61
Shares Outstanding62,153,638
10 Day Avg. Volume764,064
30 Day Avg. Volume794,627
Standard Deviation0.53
R-Squared0.05
Alpha0.05
Financial Highlights & Ratios
Price to Book (P/B)1.77
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-4.50
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue117.15
Enterprise Value/Gross Profit104.83
Enterprise Value/Ebitda-2.80
Forecast
1Y Price Target
$17.13Price Target Upside114.12% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
Fulcrum Therapeutics News
PremiumCompany Announcements
Fulcrum Therapeutics Elects Directors and Ratifies Accountant
PremiumStock Analysis & Ideas
Goldman Sachs Predicts up to 108% Rally for These 2 ‘Strong Buy’ Stocks2M ago
Bulls Say, Bears Say
Bulls Say
Clinical Data & DevelopmentLosmapimod has shown positive clinical data on the Ph3 REACH study primary endpoint reachable workspace (RWS) in the prior Ph2b study ReDUX4.
Collaborations & PartnershipsThe collaboration and licensing agreement announcement with Sanofi for the development and commercialization of losmapimod deserves more attention.
Market PotentialThe addressable market, commercial launch pace, and trajectory for FSHD have been adjusted, resulting in increased peak sales estimates.
Bears Say
Investor SentimentThe stock could trade flat since investors may believe that there is a lower probability that the company ends up in another biopharma's crosshairs.
Partnership ImpactStock's muted reaction might be a result of over-reading into the SNY deal, and some investors may interpret the partnership as removing an M&A possibility.
Regulatory IssuesPociredir hit an unexpected hiccup when the FDA placed a full clinical hold on the program due to safety concerns.
---
Ownership Overview
44.14% Insiders
14.54% Mutual Funds
14.27% Other Institutional Investors
27.05% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
FULC FAQ
What was Fulcrum Therapeutics’s price range in the past 12 months?
Fulcrum Therapeutics lowest stock price was $3.14 and its highest was $13.70 in the past 12 months.
What is Fulcrum Therapeutics’s market cap?
Currently, no data Available
When is Fulcrum Therapeutics’s upcoming earnings report date?
Fulcrum Therapeutics’s upcoming earnings report date is Aug 07, 2024 which is in 17 days.
How were Fulcrum Therapeutics’s earnings last quarter?
Fulcrum Therapeutics released its earnings results on May 13, 2024. The company reported -$0.43 earnings per share for the quarter, beating the consensus estimate of -$0.438 by $0.008.
Is Fulcrum Therapeutics overvalued?
According to Wall Street analysts Fulcrum Therapeutics’s price is currently Undervalued.
Does Fulcrum Therapeutics pay dividends?
Fulcrum Therapeutics does not currently pay dividends.
What is Fulcrum Therapeutics’s EPS estimate?
Fulcrum Therapeutics’s EPS estimate is -$0.41.
How many shares outstanding does Fulcrum Therapeutics have?
Fulcrum Therapeutics has 62,153,637 shares outstanding.
What happened to Fulcrum Therapeutics’s price movement after its last earnings report?
Fulcrum Therapeutics reported an EPS of -$0.43 in its last earnings report, beating expectations of -$0.438. Following the earnings report the stock price went down -1.606%.
Which hedge fund is a major shareholder of Fulcrum Therapeutics?
Among the largest hedge funds holding Fulcrum Therapeutics’s share is RA Capital Management. It holds Fulcrum Therapeutics’s shares valued at 110M.
---
Fulcrum Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$17.13 (114.12% Upside)
$17.13 (114.12% Upside)
Blogger Sentiment
Bullish
FULC Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 65.6K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $1.8K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 3.7%
Last 30 Days ▼ 9.0%
Last 30 Days ▼ 9.0%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
81.81%
12-Months-Change
Fundamentals
Return on Equity
-39.00%
Trailing 12-Months
Asset Growth
-27.57%
Trailing 12-Months
Company Description
Fulcrum Therapeutics
Fulcrum Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It develops new medicines and focuses on unlocking gene control mechanisms to develop small molecule therapies. Its product candidate includes Losmapimod and FTX-HbF. The company was founded by Michael R. Green, Danny Reinberg, Rudolf Jaenisch, Jeannie T. Lee, and Bradley E. Bernstein on August 18, 2015 and is headquartered in Cambridge, MA.
---
FULC Earnings Call
Q1 2024
0:00 / 0:00
---
FULC Stock 12 Month Forecast
Average Price Target
$17.13
▲(114.12% Upside)
Technical Analysis
Best Analysts Covering FULC
1 Year
1 Year Success Rate
6/11 ratings generated profit
1 Year Average Return
+24.86%
assigned a buy rating 2 months ago
Copying Matthew Biegler's trades and holding each position for 1 Year would result in 54.55% of your transactions generating a profit, with an average return of +24.86% per trade.
---